Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial. // The Lancet Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S147020452600450X?dgcid=rss_sd_all
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology. https://www.sciencedirect.com/science/article/pii/S147020452600450X?dgcid=rss_sd_all
“Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial.” The Lancet Oncology.
@article{article69014,
title = {Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial},
journal = {The Lancet Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S147020452600450X?dgcid=rss_sd_all}
}